Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jeffrey Hartgerink
University of Texas Hlth Sci Ctr Houston, Department: Dentistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
NangioTx Inc.(hereinafter referred to as the "Company")
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Company is working with a similar peptide related to that under the funded project, although their chemical structures are different and the application intended under the funded project (immunotherapy) is different than the Company’s application (Peripheral Arterial Disease (PAD)). Regardless, Rice University determined that this relationship may constitute a conflict of interest because it may be perceived that Dr. Hartgerink’s relationship with the Company could affect the design, conduct, or reporting of his research.
STINGel Immunotherapy for Treatment-Resistant Head and Neck Cancer
Project Narrative Despite advances in surgical techniques, methods of radiation therapy, and chemotherapeutic strategies, the overall 5-year survival rate for head and neck cancer has not improved much over the last few decades. In addition, the potential morbidities associated with conventional multimodal treatment can have an adverse impact on quality of life. The goal of this proposal is to investigate the mechanisms driving the surprising effectiveness of a novel immunotherapy for head and neck cancer we call ?STINGel?. By doing so, we aim to enhance our understanding of how both tumor and immune cells in the tumor environment can be manipulated to produce a strong anti-tumor effect. This will provide insights into how next-generation biomaterial-based immunotherapy platforms such as STINGel can be further improved upon to broaden the scope of cancer patients who can benefit from immunotherapy.
Filed on November 12, 2018.
Tell us what you know about Jeffrey Hartgerink's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jeffrey Hartgerink”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jeffrey Hartgerink | Rice University | Conflict of Interest | NangioTx Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.